Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.51 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.51 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.51 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.51 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5031437 | 0.97 | HRH3 (0.59) | HRH3LTA4HPRMT3CARM1PRMT6 | |
| SCHEMBL5031358 | 0.84 | HRH3 (0.53) | HRH3LTA4HSIGMAR1TMEM97TEAD3 | |
| SCHEMBL5029372 | 0.81 | HRH3 (0.56) | HRH3LTA4HSIGMAR1TMEM97TEAD3 | |
| SCHEMBL13252503 | 0.80 | LTA4H (0.58) | HRH3LTA4HSIGMAR1TMEM97TEAD3 | |
| SCHEMBL7272428 | 0.79 | CCR3 (0.61) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL17284609 | 0.79 | LTA4H (0.61) | HRH3LTA4HCARM1PRMT6PRMT8 | |
| SCHEMBL5032242 | 0.79 | HRH3 (0.53) | HRH3LTA4HCHRM1TEAD3 | |
| Hydrochloric Acid SCHEMBL25377090 | 0.79 | LTA4H (0.62) | HRH3LTA4HSIGMAR1TMEM97TEAD3 | |
| SCHEMBL6942319 | 0.78 | TEAD3 (0.56) | HRH3LTA4HSIGMAR1TMEM97TEAD3 | |
| SCHEMBL20365472 | 0.78 | MEN1 (0.53) | HRH3LTA4HSIGMAR1TEAD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670474-A4 | CYCLIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20080103148-A1 | CYCLIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-7317013-B2 | Cyclic pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| EP-1670474-A2 | CYCLIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | Parion Sciences, Inc. (US) | 2006-06-21 | — | — | EP | disclosed |
| EP-1656096-A2 | METHODS OF REDUCING RISK OF INFECTION FROM PATHOGENS | Parion Sciences, Inc. (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20050090505-A1 | Methods of reducing risk of infection from pathogens | JOHNSON MICHAEL R (US) | 2005-04-28 | — | — | US | disclosed |
| WO-2005034847-A2 | METHODS OF REDUCING RISK OF INFECTION FROM PATHOGENS | PARION SCIENCES, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20050059676-A1 | Cyclic pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2005-03-17 | — | — | US | disclosed |
| WO-2005016879-A2 | CYCLIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103148-A1 | CYCLIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | HCN4, KCNH2, CACNA1B | HRH3 1633/4885LTA4H 843/4885PRMT3 4271/4885 |
| US-20050090505-A1 | Methods of reducing risk of infection from pathogens | KCNN3, KCNN1, KCNN2 | HRH3 923/4885LTA4H 188/4885PRMT3 4283/4885 |
| US-20050059676-A1 | Cyclic pyrazinoylguanidine sodium channel blockers | HCN4, KCNH2, CACNA1B | HRH3 1633/4885LTA4H 843/4885PRMT3 4271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.